

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

HM22/1023 STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C 1100 NEW YORK AVENUE, N.W. SUITE 600 WASHINGTON DC 20005-3934

APPL	ICATION NO.	FILING DATE	TOTAL CLAIN	IS	EX	AMINER AND GROUP A	RT UNIT		DATE MAILED
	09/013,895	01/27/98	303	KA	UFMAN.	С		1646	19/23/01
First Named Applicant	NI,		35	USC	154 (b)	term ext.	##	U Day	⇒ •

TITLE OF DEATH DOMAIN CONTAINING RECEPTOR 4-NUCLEIC ACIDS AND METHODS

АТТ	Y'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
1	PF355	435-007	.200 I	V81 UTIL	TY NO	\$1280.0	0 01/23/02

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED.</u>

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.

HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above. If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
 - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
 - B. If the status is the same, pay the FEE DUE shown above.
- If the SMALL ENTITY is shown as NO:
- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give application number and batch number.

 Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

	Application No.	Applicant(s)					
	09/013,895	NI ET AL.					
Notice of Allowability	Examiner	Art Unit					
	Claire M. Kaufman	1646					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.							
 ☐ This communication is responsive to the amendment of 87/01 and telephone interview of Ex's amd't of 10/19/01. ☐ The allowed claim(s) is/are 220-522 to issue as 1-303. ☐ The drawings filed on are accepted by the Examiner. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). (a) ☐ The translation of the foreign language provisional application has been received. 							
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF							
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. CORRECTED DRAWINGS must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.							
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.							
Attachment(s)							
 1☐ Notice of References Cited (PTO-892) 3☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 5☑ Information Disclosure Statements (PTO-1449), Paper No. 3 7☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	4☐ Interview Summa 1. 6⊠ Examiner's Ame	al Patent Application (PTO-152) ary (PTO-413), Paper No ndment/Comment ement of Reasons for Allowance					

#32/F Page 2

Application/Control Number: 09/013,895

Art Unit: 1646

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jonathan Klein for Eric Steffe on October 19, 2001.

The application has been amended as follows:

In claim 275, replace "35" with -254--.

The TITLE has been changed by informal Examiner's amendment as follows:

DEATH DOMAIN CONTAINING RECEPTOR 4 -NUCLEIC ACIDS AND

METHODS--.

Election/Restrictions

Claims directed to an allowable product. Pursuant to the procedures set forth in the 232, Official Gazette notice dated March 26, 1996 (1184 O.G. 86), claims 274, 305, 325, 414, 432, 449 and 503, directed to the process of making or using the patentable product, previously withdrawn from consideration as a result of a restriction requirement, are now subject to being rejoined. Claims 274, 305, 325, 414, 432, 449 and 503 hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (703) 305-5791. Dr. Kaufman can generally be reached Monday through Thursday from 8:30AM to 12:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached at (703) 308-6564.

CILL

Application/Control Number: 09/013,895

Art Unit: 1646

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. NOTE: If applicant *does* submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. **Please** advise the examiner at the telephone number above before facsimile transmission.

Claire M. Kaufman, Ph.D.

Claum.K

Patent Examiner, Art Unit 1646

October 19, 2001

LORRAINE SPECTOR PRIMARY EXAMINER